GlassScriptPhysician profile
Ronald G Vargo
NPI 1902829526
$12,688.47
in general payments reported to CMS, 2019-2025
54 companies · $86.15 in 2025
The $86.15 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,071 · 2020: $1,783 · 2021: $2,261 · 2022: $2,080 · 2023: $2,226 · 2024: $2,182 · 2025: $86.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,480 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,479.65 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,162.72 | 2019-2025 | Ubrelvy, Vraylar, Linzess |
| Astrazeneca Pharmaceuticals LP | $1,740.89 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,218.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,153.66 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $652.53 | 2019-2023 | |
| Pfizer INC. | $620.24 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $529.65 | 2019-2024 | Jardiance, Stiolto Respimat |
| Astellas Pharma US INC | $438.82 | 2019-2024 | Veozah |
| Lilly USA, LLC | $408.53 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $381.48 | 2019-2022 | |
| Abbott Laboratories | $357.58 | 2020-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $315.40 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $311.26 | 2019-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $266.39 | 2019-2024 | Gardasil 9, Vaxelis, Pneumovax 23 |
| Allergan, INC. | $235.82 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Vargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.